Health Equity in HTA Outcomes: Navigating the New Frontier

Home / Intelligence / Webinars / Health Equity in HTA Outcomes: Navigating the New Frontier

Available On Demand

Join Value, Access and Pricing experts Max Hunt, Mary Fletcher-Louis and Pinar Bilir as they delve into the emerging role of health equity considerations as a differentiator in value narratives for global HTA (Health Technology Assessment) submissions. NICE’s proposed methods update focused on manufacturer-submitted evidence on health inequalities.

This session will explore how HTA agencies are beginning to include health equity in their access recommendations and discuss the practical impact of this trend. Our experts will share insights from Trinity Life Sciences’ Value Center of Excellence on incorporating the work of health equity teams into access materials in a way that moves the needle for payers.

Key Webinar Topics

  • The prevalence of health equity considerations in HTA outcomes
  • Practical steps to incorporate health equity into access materials
  • The importance of health equity compared to other factors
  • Emerging value drivers in the industry

Spotlight Speakers


Complete the form below to view the on-demand webinar.

We would contact you in accordance with our Privacy Policy, which we invite you to visit for details about our data privacy practices, including, where appropriate, how you may access and correct the personal data we store or withdraw consent to the collection, use or disclosure of such information. We will not share your email address or personal information. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.

This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.

Related Intelligence

Webinars

Part D in Peril: The Inconvenient Math of IRA Part D Redesign 

August 14, 2025 | 12:00 – 12:45 PM ET

Medicare Part D is undergoing its most significant transformation in decades largely driven by the IRA. What does this mean for pharmaceutical manufacturers? Join us for an engaging discussion with Max Hunt, Partner at Trinity, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage.

 Sign Up Now

Blog

Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know

March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to […]

 Read More

Blog

Pricing and Access in Germany: Innovation and Strong Evidence Rewarded

Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of […]

 Read More